Do you know what day it is?
It's hump day!
Stephen Tusa's Getting Real
Tusa said his price target of $6 was "generous" following CEO Larry Culp's warning that free cash flow from the conglomerate's industrial division is likely to remain negative this year.
"We are no longer willing to engage in a debate where the Bull case is that Power is "not that bad", the stock can be valued on $1+ (industrial free cash flow), and (GE Capital Services) is merely a zero," said JPMorgan analyst Stephen Tusa, who pressed Culp into revealing the gloomy cash flow forecast Tuesday. "We are willing to consider that zero industrial FCF is not a sustainable level but the stock is not reflecting that as a run rate with an $85 billion market cap."
Johnson & Johnson's Big Step Forward
The drug, which has been branded Spravato by J&J, is closely related chemically to ketamine, which often is used as a party drug with the nickname "Special K."
The FDA approved Spravato as a fast-acting treatment for patients who have failed to find relief with at least two antidepressants, the Associated Press reported. The drug will cost between $590 and $885 depending on the dosage and before various insurance discounts and rebates.
Dollar Tree's Reaching for the Skies
Dollar Tree (DLTR - Get Report) reported a fourth-quarter loss of $2.31 billion, or $9.66 a share, compared with a profit of $1.04 billion, or $4.37 a share, a year earlier, as the retailer recorded a $2.73 billion goodwill impairment charge related to the Family Dollar business.
Looking ahead, Dollar Tree said it expects first-quarter revenue ranging from $5.74 billion to $5.85 billion, with earnings a share in the range of $1.05 to $1.15. Analysts' are looking for revenue of $5.81 billion.